WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.

Citation for published version:

Digital Object Identifier (DOI):
10.1172/JCI76452

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Clinical Investigation

Publisher Rights Statement:
Copyright © 2015, American Society for Clinical Investigation

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited

Luke Boulter,1,2 Rachel V. Guest,1 Timothy J. Kendall,2,3 David H. Wilson,2 Davina Wojtacha,1 Andrew J. Robson,1 Rachel A. Ridgway,4 Kay Samuel,1 Nico Van Rooijen,5 Simon T. Barry,6 Stephen J. Wigmore,3 Owen J. Sansom,4 and Stuart J. Forbes1,3

1MRC Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, Edinburgh, United Kingdom. 2MRC Human Genetics Unit, Western General Hospital Campus, Edinburgh, United Kingdom. 3MRC Centre for Inflammation Research, Queens Medical Research Institute, Edinburgh, United Kingdom. 4The Beatson Institute for Cancer Research, Garscube Estate, Bearsden, Glasgow, United Kingdom. 5Department of Molecular Biology, Vrije Universiteit, Amsterdam, Netherlands. 6Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, United Kingdom.

Cholangiocarcinoma (CC) is typically diagnosed at an advanced stage and is refractory to surgical intervention and chemotherapy. Despite a global increase in the incidence of CC, little progress has been made toward the development of treatments for this cancer. Here we utilized human tissue; CC cell xenografts; a p53-deficient transgenic mouse model; and a non-transgenic, chemically induced model of CC that accurately reflects both the inflammatory and regenerative background associated with human CC pathology. Using these systems, we determined that the WNT pathway is highly activated in CCs and that inflammatory macrophages are required to establish this WNT-high state in vivo. Moreover, depletion of macrophages or inhibition of WNT signaling with one of two small molecule WNT inhibitors in mouse and rat CC models markedly reduced CC proliferation and increased apoptosis, resulting in tumor regression. Together, these results demonstrate that enhanced WNT signaling is a characteristic of CC and suggest that targeting WNT signaling pathways has potential as a therapeutic strategy for CC.

Introduction

Great effort has been made to develop WNT inhibitors for cancer treatment; however, key questions remain unanswered, including which cancers depend on WNT signaling for their growth or remain WNT responsive following therapy. This reliance on WNT signaling is still unclear in many tumors, which is a reason why the route to clinic of WNT inhibitors is uncertain. Of all cancers, colorectal cancer is most well known to be initiated by WNT-activating mutations. These mutations per se lead to insensitivity to inhibitors targeting the WNT ligand or the receptors (1). This class of drugs, which includes inhibitors of porcupine in order to inhibit WNT secretion and LRP6 to block cell surface signaling, are the best-characterized WNT inhibitors (2). An increasingly diverse collection of small molecules against the WNT pathway are being trialed clinically (3). It is therefore imperative to define cancers that are driven by WNT signaling to evaluate whether WNT inhibitors offer a tenable therapeutic strategy for cancer treatment.

Cholangiocarcinoma (CC) typically presents at an advanced stage, and tumors can be multifocal in nature. Moreover, CC is surgically unamenable and non-responsive to chemotherapy, leading to a very poor prognosis, with a survival rate of less than 5% over 5 years (4). The global incidence of CC is increasing and accounts for 15% of primary liver cancers (5).

Recent sequencing studies have shown that a subset of fluke-associated intrahepatic CCs (ICCs) have mutations in RNF43, which could confer increased WNT signaling (6). Although RNF43 mutations and alterations in APC and CTNNB1 are absent in sporadic CC (7, 8), we hypothesized that sporadic CC may require activation of WNT signaling akin to that of fluke-associated CC and that, in the absence of mutations in APC or CTNNB1, may remain sensitive to ligand or receptor inhibitors.

In this study we demonstrate that CC is a WNT-high tumor and that this WNT-high state is maintained by inflammatory macrophages in the surrounding stroma. These inflammatory macrophages express WNT7B ligand in line with what has been described in other contexts (9–11). In xenografts of human CC cells, a transgenic murine line that develops CC (12), and also a well-validated, chemically induced rat model of CC (13–17) that reflects the progression of CC in humans, we find that depletion of macrophages or inhibition of the canonical WNT pathway results in reduced tumor burden. This strategy offers, for the first time to our knowledge, a small molecule approach to the treatment of CC in vivo. Furthermore, we demonstrate efficacy of these compounds in a non-transgenic model with a natural disease history, thereby identifying a tractable therapeutic for CC.

Results

The canonical WNT pathway is activated in human CC. The canonical WNT signaling pathway is upregulated in human CC when compared with patient-matched distal, non-cancerous liver (Figure 1A and Supplemental Tables 1 and 2; supplemental material available online with this article; doi:10.1172/JCI76452DS1). As well as multiple FZD receptors, the ligands WNT7B and WNT10A are highly overexpressed in CC (Supplemental Table 2), suggesting the WNT pathway may be important in CC progression and growth. Activity through the WNT signaling pathway was assayed...
Figure 1. Canonical WNT signaling is activated in human CC. (A) mRNA expression of WNT pathway genes and WNT target genes in CC versus patient-matched non-cancerous tissue (n = 17). Represented as a 3-fold change; P < 0.05. (B) WNT7B and WNT10A mRNA expression in human CC versus non-diseased liver (n = 37 vs. n = 30). (C) Immunohistochemistry of WNT7B (green) in CD68+ macrophages (red). (D) Quantification of CD68-WNT7B+ TAMs (n = 42). (E) Immunohistochemistry for CTNNB1 (red) and BCL9 (green) in human CC and non-tumor, patient-matched liver. (F) Quantification of biliary nuclear staining for BCL9 (n = 42 per group). (G) Immunohistochemistry in non-tumor versus CC for CCND2, LEF1, BIRC5, C-MYC, and SOX9. Yellow lines, non-cancerous bile ducts; red lines, malignant biliary ducts; black arrows, nuclear positivity for C-MYC. (H) Quantification of biliary nuclear staining for CCND2, LEF1, BIRC5, C-MYC, and SOX9 in non-tumor and CC tissue (n = 42 per group). Data are presented as mean ± SEM. Mann-Whitney U test; **P < 0.01, ***P < 0.001. Photomicrograph scale bars: 50 μm (in C, right panel, 20 μm).

The canonical WNT pathway is progressively activated during CC development. Because human CC tissue reflects end-stage disease, experiments using such samples do not address whether acquisition of a highly activated WNT pathway is a hallmark of CC development. To appropriately model CC development on the background of chronic damage, inflammation and repair, as seen in human disease, we used a model of chemically induced CC using thioacetamide (TAA). TAA induces chronic damage and regeneration, culminating in CC development after 26 weeks in both mouse and rat (Figure 2A, schematic, and Supplemental Figure 2B) that histologically and transcriptionally resembles that of the human cancer (13, 15, 16).

We have recently described a transgenic model of CC in which we specifically induce p53 loss in keratin-19—expressing (KRT19-expressing) bile ducts using the tamoxifen-inducible Krt19-CreERT R26R-eYFP p53fl/WT transgenic line (12). Furthermore, recombined cells could be tracked through the presence of a silenced eYFP (Figure 2A, photomicrograph). Following tamoxifen induction and TAA administration, CC developed in Krt19-CreERT R26R-eYFP p53fl/fl mice, but not in Krt19-CreERT R26R-eYFP p53fl/wt or Krt19-CreERT R26R-eYFP p53wt/wt littermates. In Krt19-CreERT R26R-eYFP p53fl/wt mice, we found significant transcriptional upregulation of Wnt7b and Wnt10a compared with Krt19-CreERT R26R-eYFP p53fl/fl and Krt19-CreERT R26R-eYFP p53wt/wt mice (Figure 2B), suggesting that in these transgenic CCs, induced specifically with p53 deletion, the WNT pathway becomes activated. We could observe two patterns of staining with WNT7B: large inflammatory cells scattered throughout the CC stroma as well as on the surface of the malignant epithelium, which could represent autonomous signaling from the epithelial cells, or ligand being received by these cells. These data indicate activation of the canonical WNT signaling pathway by the WNT7B ligand (Figure 2C, single channels, and Supplemental Figure 2A). We stained for total CTNNB1 in these mouse tumors and could detect staining in the membrane, but also strong staining in the cytoplasm and nucleus, indicating that in these biliary tumors the canonical WNT signaling pathway is active; however, we did not see nuclear and cytoplasmic staining in parenchymal hepatocytes or non-malignant ducts (Figure 2D and Supplemental Figure 2C). To confirm that the canonical WNT signaling pathway was indeed activated, we looked for expression using 84 known CTNNB1 targets. In this matched cohort, we found upregulation of cell cycle genes including CCND2, CDKN2A, and BIRC5. Moreover, we found upregulation of multiple genes associated with a naive, undifferentiated state, including JAG1, KLF5, and SOX9 (18–20), as well as genes involved in regulation of wound repair often deregulated in cancer: PLAUR, MMP2, and MMP7 (21, 22) (Figure 1A and Supplemental Table 1). We therefore stained human CC for an obligate binding partner of the Wnt family of WNT inhibitors (although we did not see upregulation of DKK). Recent data from zebrafish have implicated KREMEN1, the non-obligate binding partner of KREMEN1 in the restriction of DKK1 activity, thereby promoting WNT activity (23). Whether expression of KREMEN1 in human CC also promotes signaling is unclear. These data together indicate that there is an intact WNT signaling cascade that is overexpressed in human CC compared with matched patient non-cancerous liver.

Informed by our initial small, matched cohort, we looked at the expression of WNT7B and WNT10A in archival tissues from 37 pathologically confirmed CC cases (both intrahepatic and peripheral CC but no CC of the common bile duct; for complete clinical parameters, see Supplemental Table 1) versus 30 cases of healthy liver (from a sudden death brain bank (Supplemental Table 1). In non-cancerous liver, these WNT ligands were expressed at low but detectable levels, potentially reflecting an active WNT pathway in perportal zone 3 hepatocytes (24) or, indeed, WNT signaling on the background of disease. There was, however, significant overexpression of the WNT7B and WNT10A ligands in CC compared with non-cancerous controls (Figure 1B). We stained for the WNT10A and WNT7B proteins in human CC. While WNT10A was undetectable at the protein level in the liver (data not shown), we found expression of WNT7B throughout the CC stroma, frequently colocalizing with a subpopulation of CD68+ macrophages (Figure 1C and Supplemental Figure 1A) and representing approximately 5% of the CD68-positive tumor-associated macrophages (TAMS) within the tumor stroma (Figure 1D).

To further confirm activation of the WNT pathway, we stained for CTNNB1, a core protein in the canonical WNT pathway. We could detect CTNNB1 in the membrane of human CC; however, we failed to detect the dephosphorylated form in the nucleus, likely due to its low stability in archival pathological specimens. We therefore stained human CC for an obligate binding partner of CTNNB1, BCL9 which is evolutionarily conserved and absolutely required for CTNNB1 to exert its canonical function (25–28). BCL9 was extensively expressed throughout the nuclei of the CC epithelium (Figure 1E and Supplemental Figure 1B), but not in the healthy bile ducts of non-cancerous matched tissue from 42 cases (0.38% in non-cancerous bile ducts vs. 67.44% in CC) (Figure 1F), confirming the importance of WNT pathway activation in human CC. We were able to stain human CC versus patient-matched non-tumor tissue (n = 42) for some of the canonical CTNNB1 targets we identified in our target array and found that an increased proportion of CC epithelial cells expressed the CTNNB1 targets CCND2 (12.58% vs. 63.52%), LEF1 (3.65% vs. 45.26%), BIRC5 (23.35% vs. 53.62%), C-MYC (0.93% vs. 4.80%), and SOX9 (95.56% vs. 98.73%) compared with non-cancerous biliary cells (Figures 1, G and H, and Supplemental Figure 1B). These targets were largely expressed in the nucleus, as expected; however, C-MYC also demonstrated some strong cytoplasmic staining, which might represent recently described, non-transcriptional functions (29, 30).
The Journal of Clinical Investigation

Figure 2. Transgenic induction of TAA in mouse has an activated WNT pathway. (A) Schematic showing strategy for generating CC using Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>fl/fl</sup> mice. (B) Wnt7b and Wnt10a mRNA expression in Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>fl/fl</sup> or Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>WT/WT</sup> versus Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>WT/WT</sup> mice (n = 6 vs. n = 4). (C) Immunohistochemistry for CTNNB1 (red), WNT7B (pink), and YFP (green) in Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>fl/fl</sup> mice. Dotted line, the tumor–non-tumor interface. (D) Immunohistochemistry for CTNNB1. Boxes, regions that are magnified in the images below; black arrows, strong nuclear staining. (E) mRNA expression of Axin2, Left1, Ccd2, Sox9, and c-Myc in Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>fl/fl</sup> or Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>WT/WT</sup> versus Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>WT/WT</sup> mice (n = 6 vs. n = 4). (F) Immunohistochemistry in Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>fl/fl</sup> tumors for active (dephosphorylated) CTNNB1, LEF1, CCND2, or SOX9 (red), and YFP (green) or C-MYC (brown). Data are presented as mean ± SEM. Mann-Whitney U test; *P < 0.05, **P < 0.01. Photomicrograph scale bars: 50 μm; insets, 10 μm.

of the WNT targets Axin2, Left1, Ccd2, Sox9, and c-Myc and found that there was upregulated expression of these genes in Krt19-CreER<sup>T</sup> R26R-eYFP p53<sup>fl/fl</sup> but not p53<sup>WT/WT</sup> or p53<sup>WT/WT</sup> mice (Figure 2E). Moreover, we were able to detect dephosphorylated (nuclear) CTNNB1 (detecting an epitope distinct from that used in Figure 2D), nuclear LEF1, CCND2, SOX9, and C-MYC in the p53<sup>fl/fl</sup> YFP<sup>+</sup> tumors (Figure 2F), indicating WNT signaling activity. We failed to see nuclear C-MYC staining in the nuclei of hepatocytes or non-malignant biliary epithelium (Supplemental Figure 2B).

Human TRP53 (p53) is mutated in only a small proportion (9.3%) of spontaneous, non-liver fluke-associated CCs, indicating that a complex and heterogeneous group of mutations are capa-
ble of driving CC progression (31). Our murine model with Cre recombinase–induced p53 loss, therefore, is unlikely to represent the broad mutational profile seen in human CC. In order to assess experimentally how the WNT pathway regulates CC growth without prior genetic modification, we used TAA-induced carcinogenesis in rats as a more genetically appropriate model of CC.

Throughout the early stages of the rat TAA model of CC (up to 16 weeks), membranous CTNNB1 was detectable in the cell membrane of KRT19-positive regenerating ductules (Figure 3A and Supplemental Figure 2B). During CC formation (from week 2D), we were able to detect high levels of dephosphorylated CTNNB1 in the nucleus of the epithelial component of CC (in 56% of epithelial cells) (Figure 3B and Figure 3E, graph). The canonical WNT pathway was highly activated in 26-week TAA-treated versus non-TAA age-matched controls. Upregulated targets included cell cycle regulators such as Ccnd2, Cdkn2a, and Ctgf, as well as targets associated with a progenitor phenotype, including Jag1, Klfs, and Sox9. These transcripts reflect a subset of genes that we found upregulated in human CC (Figure 1A), indicating that the TAA rat model mirrors the elevated WNT system we saw in humans (Figure 3C and Supplemental Table 3). Making use of our rat TAA time course, we were able to study the transcriptional changes of WNT pathway genes over time as the TAA model transitions from repair to carcinogenesis. The ligands Wnt10a and Wnt7b were both upregulated in the rat TAA model. Wnt10a transcription increased early, during the regenerative phase of this inflammatory model; however, Wnt7b increased in line with CC growth (Figure 3D). We also found that Rspo1 expression was significantly upregulated in line with significant transcriptional induction of Lgr4, Bcl9, Birc5, Axin2, and Rnf43, the latter of which is an E3 ligase responsible for WNT-FZD receptor complex turnover. Rnf43 is mutated in a subset of fluke-associated CC in humans and results in a hyperactivated WNT signaling cascade (ref. 6 and Figure 3D). In addition to this, we found that aurora kinases A, B, and C (Aurka, Aurkb, and Aurkc) were expressed, with Aurka being highly upregulated during CC development, whereas Aurkb and Aurkc were increased but to a lesser degree throughout TAA treatment (Figure 3D). To confirm that the canonical WNT signaling pathway was indeed activated in the epithelial component of TAA-induced ICC, we stained samples cutaneously implanted in the flanks of CD1 nude mice. Within 21 days all mice had palpable tumors at the injection site. Xenografted mice were given liposomal clodronate (Lipclod) to selectively deplete phagocytic macrophages; GW2580 or AZD7507 (Figure 5A) to inhibit the activation of CSF receptor 1 (CSFRI), thereby preventing monocyte differentiation into macrophages; or appropriate vehicle alone (41–44). Tumors were isolated 8 hours after the final dose of each compound. The epithelial component of CC-LP-1, SNU-1079, or WITT-1 cells was negative for CSFR1; however, a population of small infiltrating cells expressed the receptor (Supplemental Figure 3A). In Lipclod–, GW2580–, and AZD7507–treated mice, we observed a significant decrease in the number of CD68 macrophages in the xenografts (Figure 5B and Supplemental Figure 3B). Mice with CC-LP-1 and SNU-1079, but not WITT-1, xenografts demonstrated both reduced tumor volume and mass after treatment with Lipclod, GW2580, and AZD7507 (Figure 5C and Supplemental Figure 3C). Furthermore, of the 8 SNU-1079 xenografts that were palpable at 3 weeks, only 4 from the GW2580 group and 6 from the AZD7507 group were large enough to recover at week 6, as they were no longer palpable and too small to detect. In the CC-LP-1 group, only 3 of the 8 tumors were detectable at 6 weeks. (In the WITT-1 line, 7 xenografts were recovered from the GW2580 and 8 from the AZD7507 group.) Depletion of mac-
rophages using Lipclod, GW2580, or AZD7507 in all 3 xenografted lines resulted in a reduction in murine Wnt7b expression at the mRNA level (Figure 5D and Supplemental Figure 3D). Murine and human WNT7B share 99% peptide similarity; therefore, we expected murine WNT7B would be sufficient to activate normal canonical WNT signaling in human CC lines. Concurrent with the loss of macrophages and host macrophage-derived murine Wnt7b expression, we found reduced expression of the human pro-proliferation genes BIRC5, CCND2, and CCNE (Supplemental Figure 3, E and H) and an increase in expression of BAX1 in CC-LP-1 and SNU-1079 but not WITT-1 xenografts (Supplemental Figure 3, G and J), indicating ablation of macrophages and by extension loss of WNT signal, reduced proliferation, and induced apoptosis, thereby reducing tumor burden in CC-LP-1 and SNU-1079

Figure 3. The WNT pathway is activated in a rat model of CC. (A) Immunohistochemistry for CTNNB1 (red) and KRT19 (green) in precancerous TAA rats. (B) Immunohistochemistry for CTNNB1 and KRT19 in cancerous TAA rats. White arrows in insets, nuclear positivity of CTNNB1; dotted line, tumor interface. (C) mRNA expression of WNT pathway targets in 26-week TAA versus matched non-treated controls (n = 6 per group). (D) mRNA expression of WNT ligands Wnt10a and Wnt7b; WNT pathway effectors Rspo1, Bcl9, Birc5, Axin2, Rnf43, and Lgr4; and cell cycle targets Aurka, Aurkb, and Aurkc. (E) Immunohistochimistry in rat CC for CTNNB1 (red), BIRC5 (green), and LEF1 and CCND2 (brown). Graph: Quantification of epithelial nuclear staining in 26-week TAA rat (n = 10). (F) Immunohistochemistry for WNT7B (red) and RSPO-1 (green) in TAA-induced CC. Data are presented as mean ± SEM. Kruskal-Wallis test; ***P < 0.001. Photomicrograph scale bars: 50 μm; insets, 10 μm.
xenografts in vivo. We confirmed this observation by staining for Ki-67 and TUNEL to look for proliferation and cell death, respectively, in our xenografts. We found an obvious reduction in Ki-67 positivity (photomicrographs, Supplemental Figure 3, F and I) and an increase in TUNEL positivity (photomicrographs, Supplemental Figure 3, G and J) in macrophage-depleted CC-LP-1 and SNU-1079 but not WITT-1 xenografts. The inconsistency seen in the WITT-1 group could reflect the extrahepatic origin of the WITT-1 line (45), which suggests it has a growth kinetic very different from the intrahepatic lines; that fact that it is less reliant on macrophage activation; or, alternatively, that it undergoes proliferative compensation from a signal that is non–macrophage derived.

Subcutaneous xenografts do not represent CC in terms of natural disease progression or stromal microenvironment. Therefore, we used our TAA-induced rat model of CC to ask whether macrophage ablation in CC alters canonical WNT pathway activity and whether this regulates in situ growth of CC (Figure 6A). Following administration of liposomal clodronate, both CD68+ (inflammatory) and CD163+ (resident) macrophages were significantly reduced in number (Supplemental Figure 4A). In line with this loss of macrophages, we found a significant reduction in the expression of Wnt7b and also a non-significant reduction in the M-BOAT family member porcupine (Porcn), which is necessary for WNT ligand secretion (46), but not Wnt10a, indicating that this ligand is not derived from macrophages in this model of CC (Figure 6A). Immunostaining TAA tumor treated with Lipclod versus vehicle for WNT7B. In vehicle-treated animals, we could detect the presence of WNT7B on the cancerous duct (Figure 6C). Following macrophage depletion, however, we were unable to detect WNT7B protein on these malignant ducts (Figure 6C). We further analyzed activation of the WNT pathway by looking at CTNNB1 targets in tissue containing CC from macrophage-depleted versus control groups. Macrophage-depleted CC showed a global downregulation of CTNNB1 targets in vivo. We found significant downregulation of genes known to regulate cell cycle, including Ccnd1, Ctgf, and Hedgehog receptors Ptch1 and Smo. Moreover, we found significant downregulation of genes known to promote a progenitor phenotype, including Jag1 and Klf5 (Figure 6D and Supplemental Table 3). The net consequence of macrophage depletion and WNT pathway inactivation in CC was a striking 86% reduction in tumor number and 90% reduction in tumor volume (Figure 6, E and F). To confirm that macrophage ablation was preventing activation of the canonical WNT pathway, we stained remaining CC rudiments and control CCs for nuclear CTNNB1 and BIRC5. We found CTNNB1 was confined to the cell membrane in cancer following macrophage depletion (Supplemental Figure 4B) and that it did not translocate to the nucleus as in the control tissue. BIRC5 was largely lost in the epithelial compartment of the tumor following macrophage depletion vs. 25.56% in Lipclod treated, Supplemental Figure 4C). Expression of BIRC5 persisted in non-epithelial components of the tumor, indicating that macrophage depletion targets WNT activity in the epithelial compartment, whereas expression of BIRC5 is regulated in a non-WNT-dependent manner in the stroma. We also investigated the expression of known CTNNB1 targets SOX9, LEF1, and CCND2 in TAA-induced CCs treated with Lipclod versus vehicle.
treatment of CC; therefore, we sought to interrogate the WNT-
CTNNB1 pathway in CC directly. In our PCR arrays of human CC,
we found that both CTBP1 and PORCN were highly upregulated
(Figure 1A). CTNNB1-CTBP activates transcription of pro-prolifer-
ative WNT target genes (47), whereas PORCN is required for the
palmitoylation of WNT ligands, thereby regulating their secretion
(48, 49). Thus, we specifically inhibited either the CTNNB1-CTBP
interaction or the activity of PORCN in human CC cells in vitro
with the small molecule ICG-001 or C-59, respectively. These
compounds have been used to great effect in other systems (47 ,
50–53) to therapeutically inhibit the canonical WNT signaling
cascade. Five human CC cell lines, CC-LP-1, SNU-1079, WITT-1,
SNU-1196, and CC-SW-1 (39, 40, 54), expressed both CTNNB1
and WNT7B in vitro (Supplemental Figure 5A; negative staining
control, Supplemental Figure 8B). Inhibition of CTNNB1-CTBP or
PORCN with ICG-001 or C-59, respectively, resulted in a reduction
in cell number in a dose-dependent manner (Figure 7A) across all

We found a significant reduction in the epithelial nuclear positiv-
ity of SOX9 (96.05% in control vs. 75.54% in Lipclod treated, Sup-
plemental Figure 4D), LEF1 (69.14% in control vs. 65.30% in Lip-
clod treated, Supplemental Figure 4E), and CCND2 (30.40% in
control vs. 13.16% in Lipclod treated, Supplemental Figure 4F). In
vehicle-treated animals, Ki-67 was readily detected in the malig-
nant CC epithelium (in 52.9% of CC epithelia); however, TUNEL
positivity was rare (in 2.7% of CC epithelia) (Supplemental Figure
4G). Upon macrophage depletion we detected notable regions
ranging from groups of cells to entire ductules of the biliary epithe-
lium that stained positive for TUNEL (18.17% positive). Moreover,
we found a significant drop in the number of CC epithelial cells
that were positive for Ki-67 (28.14%), indicating that reduction in
tumor load is in part mediated through the induction of apoptosis
and loss of proliferation in vivo (Supplemental Figure 4G).

**CTNNB1 inhibition regulates cell cycle progression in CC.**
Systems depletions of macrophages is not a tenable therapy for the
treatment of CC; therefore, we sought to interrogate the WNT-
CTNNB1 pathway in CC directly. In our PCR arrays of human CC,
we found that both CTBP1 and PORCN were highly upregulated
(Figure 1A). CTNNB1-CTBP activates transcription of pro-prolifer-
ative WNT target genes (47), whereas PORCN is required for the
palmitoylation of WNT ligands, thereby regulating their secretion
(48, 49). Thus, we specifically inhibited either the CTNNB1-CTBP
interaction or the activity of PORCN in human CC cells in vitro
with the small molecule ICG-001 or C-59, respectively. These
compounds have been used to great effect in other systems (47 ,
50–53) to therapeutically inhibit the canonical WNT signaling
cascade. Five human CC cell lines, CC-LP-1, SNU-1079, WITT-1,
SNU-1196, and CC-SW-1 (39, 40, 54), expressed both CTNNB1
and WNT7B in vitro (Supplemental Figure 5A; negative staining
control, Supplemental Figure 8B). Inhibition of CTNNB1-CTBP or
PORCN with ICG-001 or C-59, respectively, resulted in a reduction
in cell number in a dose-dependent manner (Figure 7A) across all
Reduction in the viability of cells treated with either ICG-001 or C-59 was due to both reduced proliferation of CC cells and increased apoptosis, as demonstrated by reduced BrdU uptake and increased caspase-3/7 activity in CC cells (Figure 7, B and C). Inhibition of the canonical WNT signaling pathway using both small molecule strategies reduced the expression of numerous WNT target genes in all cell lines tested (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4). There was no stereotypical group of targets that was downregulated in CC lines following ICG-001 or C-59 treatment; this may reflect the diverse origins of these CC lines or highlight how canonical WNT signaling promotes survival through multiple pathways. To ascertain how inhibition of canonical WNT signaling was exerting its effect to reduce CC cell numbers, we assessed cell cycle genes that were diversely regulated in ICG-001– or C-59–treated versus vehicle-treated cells (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4). There was no stereotypical group of targets that was downregulated in CC lines following ICG-001 or C-59 treatment; this may reflect the diverse origins of these CC lines or highlight how canonical WNT signaling promotes survival through multiple pathways. To ascertain how inhibition of canonical WNT signaling was exerting its effect to reduce CC cell numbers, we assessed cell cycle genes that were diversely regulated in ICG-001– or C-59–treated versus vehicle-treated cells (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4). There was no stereotypical group of targets that was downregulated in CC lines following ICG-001 or C-59 treatment; this may reflect the diverse origins of these CC lines or highlight how canonical WNT signaling promotes survival through multiple pathways. To ascertain how inhibition of canonical WNT signaling was exerting its effect to reduce CC cell numbers, we assessed cell cycle genes that were diversely regulated in ICG-001– or C-59–treated versus vehicle-treated cells (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4). There was no stereotypical group of targets that was downregulated in CC lines following ICG-001 or C-59 treatment; this may reflect the diverse origins of these CC lines or highlight how canonical WNT signaling promotes survival through multiple pathways. To ascertain how inhibition of canonical WNT signaling was exerting its effect to reduce CC cell numbers, we assessed cell cycle genes that were diversely regulated in ICG-001– or C-59–treated versus vehicle-treated cells (Figure 7, D and E, Supplemental Figure 6, A and B, and Supplemental Table 4).
Inhibition of canonical WNT signaling inhibits CC growth. Our data demonstrate that the WNT signaling pathway is required for proliferation and survival of CC in xenografts. To confirm that these findings are translatable into a pathophysiological model of CC in vivo, we gave the CTNNB1-CTBP inhibitor ICG-001 to rats treated with TAA for 26 weeks. Furthermore, as we hypothesize that CC is still dependent on WNT ligand due to relatively infrequent mutations in Apc or Ctnnb1, we inhibited WNT ligand secretion using the small molecule C-59, as this compound also inhibited human CC growth in vitro and in xenografts (2, 53, 55, 56). We administered ICG-001, C-59, or vehicle alone once tumors had established at week 21, through to week 26, during which tumors normally undergo rapid growth (Figure 8A). Inhibition of the canonical WNT pathway with either ICG-001 or C-59 resulted in a marked decrease in tumor burden throughout the liver lobe (Figure 8B). Reduced tumor penetrance was largely due to a decrease in tumor number in both ICG-001- and C-59–treated animals compared with vehicle alone (76% and 64% reduction respectively) (Figure 8, B and C). Moreover, the size of the remaining tumors was significantly reduced by 71% in the ICG-001–treated group and 55.1% in the C-59–treated group compared with vehicle (Supplemental Figure 6, G and K).

In C-59– or ICG-001–treated rats, the remaining cancerous epithelia still had regions of proliferation, potentially reflecting a population of WNT inhibitor-resistant cancer cells (vehicle 63.78%, ICG-001 49.67%, and C-59 49.73% Ki-67 CC epithelial cells); however, there were also large regions of TUNEL positivity in the cancerous epithelium (vehicle 0.86%, ICG-001 6.529%, and C-59 2.951%). BIRC5 was also reduced in the epithelial and stromal cell compartments in ICG-001–treated CC (Figure 9, A and B). Inhibition with C-59 greatly reduced the nuclear positivity of BIRC5 in the cancerous epithelium (71.91% vs. 3.501%). BIRC5 was also reduced in the epithelial compartment (67.83% vs. 20.62%) (Figure 9, C and D); however, strong staining for BIRC5 in non-epithelial cell types in the CC stroma could still be observed, indicating non-epithelial expression of BIRC5 is independent of the WNT signal (Figure 9C). ICG-001 did not completely inhibit the translocation of CTNNB1 to the nucleus in CC (Figure 9A, 71.91% vs. 28.90%); however, this inhibitor elicits its effect downstream of nuclear translocation of CTNNB1. In ICG-001–treated CC, we found the CTNNB1-CTBP target BIRC5 was almost completely lost in the epithelium of CC xenografts (Supplemental Figure 6, E, I, and M). Concurrently we found an increase in apoptosis reflected in expression of human BAX1 within the CC-LP-1 and SNU-1079, but not WITT-1, CC xenografts (Supplemental Figure 6, F, J, and N).

Inhibition of canonical WNT signaling pathway alters cell viability in vitro. (A) MTT assay using SNU-1079, CC-SW-1, SNU-1196, CC-LP-1, and WITT-1 CC lines treated with increasing concentrations of ICG-001 or C-59. Dose response data are presented as the mean of 3 experimental replicates that were run in triplicate. (B) Quantification of caspase-3/7 activity and BrdU incorporation with increasing concentrations of ICG-001 in SNU-1079, CC-SW-1, SNU-1196, CC-LP-1, and WITT-1 CC lines. (C) Quantification of caspase-3/7 activity (left graph) and BrdU incorporation (right graph) with increasing concentrations of C-59 in SNU-1079, CC-SW-1, SNU-1196, CC-LP-1, and WITT-1 CC lines. (D) mRNA expression of WNT target genes and cell cycle genes in CC-LP-1 and SNU-1079 cells following inhibition with ICG-001. Data are presented as >2-fold-change. (E) mRNA expression of WNT target genes and cell cycle genes in CC-LP-1 and SNU-1079 cells following inhibition with C-59. Data are presented >2-fold change. Dose response data are presented as the mean of 3 experimental replicates that were run in triplicate. Kruskal-Wallis test: **P < 0.01, ***P < 0.001. Gene expression data represent pooled material from 3 experimental replicates run in triplicate.
through the transcription of a broad panel of target genes that have been implicated in cell cycle transition, mitotic spindle assembly, and DNA segregation (57–61). However, the function of WNT signaling in both homeostasis and tumorigenesis is not simple, as WNT signaling appears to have different functions at different signaling levels, and so the well-described on-off model of WNT signaling is unlikely to be borne out in complex cellular environments (36, 62). Understanding how the WNT signaling cascade is regulated in a complex cellular environment, where multiple cellular components will influence the growth of the cancer and WNT activity, will be important for the development of therapeutic approaches to the treatment of WNT-dependent cancers. CC represents an increasingly prevalent global challenge and remains untreatable. In many other malignancies where the WNT pathway activation is a hallmark of disease progression, blockade of the canonical WNT signal has failed as standard-of-care treatment, with tumors being refractory to these new WNT inhibitors. The WNT signaling pathway is complex and has multiple nodes of interaction with other signaling cascades. Because of this, WNT signaling sits in a highly regulated hierarchy in which it is influenced by both auto-regulatory and para-regulatory signals. There has been a large body of work to explain why these recombinant protein or small molecule approaches have failed to achieve clinical impact. In general, lack of responsiveness can be largely explained by mutations in core elements of the canonical WNT pathway such as CTNNB1 or APC, which function downstream of many canonical inhibitors and represent one of the most frequently mutated complexes in multiple cancer types (3, 63, 64). While knowing the common mutation profiles allows drug discovery and compound development to be focused for these tumors, it is important to also recognize that the presence of mutations in core pathway components does not mean that that pathway is critical for tumor growth per se.

Recent exome sequencing on human CC from both spontaneous and fluke-associated CC has identified multiple mutated candidates that could act as drivers in CC (6, 31). Of note is that RNF43, an E3 ligase required for normal FZD receptor turnover following ligand binding, is regularly mutated in fluke-associated CC, but not in spontaneous CC (31). Interestingly, and unlike other gastrointestinal cancers such as hepatocellular carcinoma (HCC) and colon cancer, the CTNNB1 and APC loci are infrequently mutated, indicating CC could be susceptible to WNT inhibitor-based therapies, as there are no commonly described mutations downstream of the point of inhibition (i.e., APC or CTNNB1) that would allow these tumors to grow in a WNT ligand-independent manner.

Inflammatory macrophages in other systems have been shown to contribute to repair and carcinogenesis through the production of WNT ligands (9, 10). This process appears to be critical in the mediation of epithelial repair across a variety of organs, including kidney, liver, and colon (9, 10, 65). Importantly, and as also supported by our data, the role of WNT signaling in regeneration by macrophages appears to be orchestrated by M2 (alternatively activated) macrophages, which are able to stimulate the canonical WNT signaling cascade in colonic epithelial cells; however, M1 (classically activated) macrophages, in the colon at least, cannot (65). In a variety of diseased tissues and cancers, macrophage-derived WNT ligands play diverse roles and have been implicated in proliferation, inhibition of the autophagosome, and also metastasis (10, 65–67). The presence of certain monocyte subsets in CC has been correlated with a worse prognosis in CC (68), identifying the inflammatory milieu as a critical source of survival signals in CC growth.

In this study, we demonstrate a link between disease progression and WNT activation in human CC and both a mouse transgenic and chemically induced rat model, in which activation of the WNT signaling pathway correlated with growth of CC. More important, perhaps, we clearly show that inhibition of the canonical WNT pathway through inhibition of CTNNB1-CTBP signaling or indeed through inhibition of secretion of WNT ligand in vivo significantly reduces both tumor size and tumor number, revealing therapeutic WNT inhibition as a potential treatment for CC in humans.

**Methods**

**Cell culture.** CC-LP-1 and CC-SW-1 were provided by T.L. Whiteside, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. WITT-1 donated by J.P. Iredale, MRC Centre for Inflammation Research (39, 40). SNU-1196 and SNU-1079 were purchased from the Korean Cell Line Bank (http://cellbank.snu.ac.kr/english/index.php). These cells were tested for the presence of mycoplasma in-house at the beginning of the study and were found to be negative. In this study cells were maintained in DMEM with glutamine and 5% FCS (PAA) at 37°C and with 5% CO$_2$. For in vitro cell viability assays, cells were plated at a density of $1 \times 10^4$/cm$^2$. All cell lines were treated for 5 days with ICG-001 (Tocris) or vehicle alone or 10 days with C-59 (Cellagen) inhibitor or vehicle alone at the concentrations shown in Figure 6 and Supplementary Figure 4. In experiments that were not dose response studies, cells were incubated with ICG-001 at 7.5 μM and C-59 at 100 nM. In these studies vehicle was always volume-matched DMSO. MTT assay was conducted using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (5 mg/ml) (Sigma-Aldrich) dissolved in PBS (Sigma-Aldrich). Cells were treated for 12 hours, and MTT crystals were dissolved in DMSO and read at 570/690 nm using a Fluostar Omega (BMG Labtech). BrdU incorporation assay (Cell Signaling Technology) and caspase-3/7 activity assays (Promega) were conducted as described in the manufacturer’s instructions.

Human tissue was collected under approval of the University of Edinburgh ethics committee and diagnosed by the NHS Lothian/University of Edinburgh Pathology Department. Healthy liver was provided by the NRS BioResource, NHS Lothian. All tissues were collected with informed consent. Tissue microarrays (TMAs)–tissue block LVC1261 were purchased from Pantomics.
**Animal studies.** All animal work was conducted in accordance with the UK Home Office regulations. Animals were housed in 12-hour light/12-hour dark cycles and were given access to food and water ad libitum. The number of animals used in each experiment was calculated based on an α value of 0.05 and a power of 0.90 using data from either pilot studies or based on previous work.

**Human ICC xenograft models.** Male CD1 nude mice (Harlan) were injected subcutaneously with $5 \times 10^5$ human ICC cells from human cell line WITT-1, CC-LP-1, or SNU-1079 ($n = 24$ in all cases) suspended in culture media/RGF Matrigel (Gibco) mix (1:1). Cells were engrafted bilaterally in the flank and allowed to form tumors over 3 weeks. Once palpable tumors had formed, mice were randomized into...
were precipitated using isopropanol. The precipitate was applied to an RNeasy Mini column (QIAGEN), and the manufacturer’s protocol was followed. Isolated RNA was quantified using a NanoDrop 1000, and then 1 μg was reverse transcribed using the QuantiTect RT kit (QIAGEN) as per the manufacturer’s instructions. 25 ng of cDNA was assayed using SYBRfast qPCR reagents and Quantifast primers from QIAGEN. For a complete list of primers, see Supplemental Table 6. All analysis was conducted using a LightCycler 480-II (Roche). qPCR pathway arrays were purchased from SABiosciences and were used as per the manufacturer’s protocol.

**Statistics.** Quantification of xenograft size was performed in a blinded manner, and size of tumors in vivo was performed as a double-blind analysis by an independent clinically trained pathologist. For quantification of TMA core in human samples, the whole biopsy core was photographed in a blinded fashion and counted. For quantification of rat tissue, 10 pathologically discrete tumors were selected, imaged in their entirety, and counted in blinded fashion. All experimental groups were analyzed for normality using a D’Agostino-Pearson omnibus test. Groups that were normally distributed were compared with either a 2-tailed Student’s test (for analysis of 2 groups) or using 1-way ANOVA to compare multiple groups. Non-parametric data were analyzed using a Wilcoxon–Mann–Whitney U test when comparing 2 groups or a Kruskal–Wallis test when comparing multiple non-parametric data. Throughout, \( P < 0.05 \) was considered significant. \( * \) \( P < 0.05 \), \( ** \) \( P < 0.01 \), \( *** \) \( P < 0.001 \). Data are presented as mean with SEM for parametric data or median with SD for non-parametric data.

**Study approval.** All studies involving human tissue were approved by the University of Edinburgh and NHS Lothian Academic and Clinical Central Office for Research Development (ACCORD) tissue governance unit. All tissue was collected with informed consent. Animal studies were approved by the University of Edinburgh Animal Welfare and Ethical Review Body (AWERB) and licensed by the UK Home Office.

**Acknowledgments**

L. Boulter is funded by the Medical Research Council (G1000868/979000), Cancer Research UK (C26848/A14889), and the Alan Morement Memorial Fund. S.J. Forbes is funded by the Medical Research Council (G1000868/979000), Cancer Research UK (C26848/A14889), the Alan Morement Memorial Fund, and UK Regenerative Medicine Platform (MR/M007588/1). A.J. Robson is funded by a personal MRC fellowship, and O.J. Sansom is funded by Cancer Research UK and the European Research Council. R.V. Guest and T.J. Kendall are funded by personal Wellcome Trust fellowships. Clodronate (Cl,MDP) was a gift from Roche Diagnostics. We thank the NRS BioResource for provision of human tissue and Rachel Berry for provision of embryonic tissue, Robert Walker for technical assistance, and E.M.J. Boulter-Comer for proofreading of the manuscript.

Address correspondence to: Stuart J. Forbes, MRC Centre for Regenerative Medicine, 5 Little France Drive, Edinburgh, EH16 4UU, United Kingdom. Phone: 44.0.131.651.9500; E-mail: stuart.forbes@ed.ac.uk.

*The Journal of Clinical Investigation* 2015;125:3183-3204. doi:10.1172/JCI76452


